CN114732887B - Traditional Chinese medicine composition for treating bronchial asthma - Google Patents

Traditional Chinese medicine composition for treating bronchial asthma Download PDF

Info

Publication number
CN114732887B
CN114732887B CN202210416245.7A CN202210416245A CN114732887B CN 114732887 B CN114732887 B CN 114732887B CN 202210416245 A CN202210416245 A CN 202210416245A CN 114732887 B CN114732887 B CN 114732887B
Authority
CN
China
Prior art keywords
parts
chinese medicine
traditional chinese
bronchial asthma
medicine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210416245.7A
Other languages
Chinese (zh)
Other versions
CN114732887A (en
Inventor
张常喜
王成娟
贾丽
孙雪
曹腊梅
张凤春
李甜甜
郭涛
李冀
李燕妮
徐佰洋
孙洪涛
张安妮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ningxia Hui Autonomous Region Chinese Medicine Hospital And Institute Of Traditional Chinese Medicine
Original Assignee
Ningxia Hui Autonomous Region Chinese Medicine Hospital And Institute Of Traditional Chinese Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningxia Hui Autonomous Region Chinese Medicine Hospital And Institute Of Traditional Chinese Medicine filed Critical Ningxia Hui Autonomous Region Chinese Medicine Hospital And Institute Of Traditional Chinese Medicine
Priority to CN202210416245.7A priority Critical patent/CN114732887B/en
Publication of CN114732887A publication Critical patent/CN114732887A/en
Application granted granted Critical
Publication of CN114732887B publication Critical patent/CN114732887B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/238—Saposhnikovia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/268—Asarum (wild ginger)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533—Leonurus (motherwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/64—Orobanchaceae (Broom-rape family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/714—Aconitum (monkshood)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a traditional Chinese medicine composition for treating bronchial asthma, which takes antler, motherwort fruit and clove as monarch drugs, takes cicada slough, stiff silkworm, radix bupleuri, turmeric, asarum, thin aconite, golden boiling grass, white mustard seed and perilla seed as ministerial drugs, astragalus root, bighead atractylodes rhizome, divaricate saposhnikovia root, perilla leaf, teasel root and cistanche as adjuvant drugs and takes rhizoma polygonati as conductant drugs. The medicines exert the efficacy synergistically, the medicines are combined to be suitable for ascending and descending, the internal and external are combined, the lung qi is convenient for descending, the qi and blood of the whole body are smooth, so that the effects of warming lung and reducing phlegm, descending qi and relieving cough, and relieving asthma and receiving kidney are achieved. The invention has better treatment effect on patients with bronchial asthma in clinical application.

Description

Traditional Chinese medicine composition for treating bronchial asthma
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating bronchial asthma.
Background
Bronchial asthma is a chronic airway inflammatory disease caused by various reasons, is mainly characterized by reversible airflow limitation and airway hyperreactivity, and is often accompanied by symptoms such as repeated wheezing, chest distress, cough (or the like), and the frequency and symptoms of early and late attacks are most obvious. When asthma repeatedly attacks, the survival rate and life quality of patients are seriously reduced, the morbidity, hospitalization rate and death rate of asthmatic patients are increased year by year, and the patients repeatedly attack the asthma, pass through medicines and hospitalization for a long time, so that the life quality is low, meanwhile, the economic burden is increased, and the asthma becomes an important public health problem of the current society. Early discovery and early diagnosis of asthma are extremely important for the treatment of asthma. The lung function examination is an important objective index in the diagnosis and curative effect evaluation of asthma, the degree of airflow limitation and whether the airflow limitation is reversible or not, and meanwhile, the airway inflammation condition can be monitored to a certain extent.
The traditional effective medicines for treating the bronchial asthma are mostly western medicines, but the western medicines have larger side effects, strong dependence and smaller improvement effect on the lung function of patients, and treat symptoms without root cause.
Disclosure of Invention
Aiming at the defects pointed out in the background technology, the invention provides a traditional Chinese medicine composition for treating bronchial asthma, and aims to solve the problems existing in the prior art in the background technology.
In order to achieve the above purpose, the invention adopts the following technical scheme:
a traditional Chinese medicine composition for treating bronchial asthma is prepared from the following raw materials: cornu Cervi, fructus Leonuri, flos Caryophylli, periostracum Cicadae, bombyx Batryticatus, bupleuri radix, curcuma rhizome, herba asari, radix Aconiti lateralis Preparata, herba Hedyotidis Diffusae, semen Sinapis Albae, fructus Perillae, radix astragali, atractylodis rhizoma, radix Saposhnikoviae, folium Perillae, radix Dipsaci, cistanchis herba, and rhizoma Polygonati.
The traditional Chinese medicine composition is prepared into watered pills, and is orally taken by patients, and through clinical observation for 2 months, the main symptoms of asthma, cough, expectoration, chest fullness and stuffiness, wheezing sound and the like of asthmatic patients are obviously improved; the traditional Chinese medicine composition has the advantages of good curative effect on the secondary symptoms of dark complexion, cold limbs, choking cough, flushing, polydipsia, cough with weak voice, shortness of breath and the like of asthma patients. And compared to FEV of patient lung function before and after treatment 1 ％pred、FEV 1 FVC was improved, indicating that the above-described herbal composition can improve lung function in patients to some extent.
The prescription adopts 3 monarch drugs, 9 ministerial drugs, 6 adjuvant drugs and 1 guide drug, the monarch drugs, the ministerial drugs, the adjuvant drugs and the guide drugs cooperatively exert the drug effect, the drugs are suitable for lifting, internal and external communication, up and down communication, lung qi is suitable for dispersing and descending, qi and blood of the whole body are smooth, so that the effects of warming lung and reducing phlegm, descending qi and relieving cough, relieving asthma and receiving kidney are achieved, and the ascending and descending of qi are normal, so that asthma is self-leveling. Research shows that the medicine has better treatment effect on patients with bronchial asthma in clinical application.
Preferably, through pharmacological analysis of each medicine, exertion degree of medicine effect and mutual synergistic effect research, the dosage relationship of each medicine in the preliminarily obtained traditional Chinese medicine composition for treating bronchial asthma is as follows: the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 15-25 parts of antler, 15-25 parts of motherwort fruit, 5-10 parts of clove, 8-15 parts of cicada slough, 15-25 parts of stiff silkworm, 5-10 parts of bupleurum, 5-10 parts of turmeric, 5-10 parts of asarum, 15-20 parts of thin aconite, 8-15 parts of golden-boiling grass, 5-10 parts of white mustard seed, 10-15 parts of perilla seed, 25-35 parts of astragalus root, 15-25 parts of bighead atractylodes rhizome, 15-20 parts of divaricate saposhnikovia root, 8-15 parts of perilla leaf, 12-18 parts of teasel root, 12-18 parts of cistanche deserticola and 12-18 parts of rhizoma polygonati.
Preferably, the prescription with the best drug effect obtained by further clinical test effect analysis is as follows: the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 20 parts of antler, 20 parts of motherwort fruit, 9 parts of clove, 10 parts of cicada slough, 20 parts of stiff silkworm, 6 parts of radix bupleuri, 8 parts of turmeric, 9 parts of asarum, 18 parts of thin aconite, 10 parts of golden-point grass, 8 parts of white mustard seed, 12 parts of perilla fruit, 30 parts of astragalus root, 20 parts of bighead atractylodes rhizome, 18 parts of divaricate saposhnikovia root, 10 parts of perilla leaf, 15 parts of teasel root, 15 parts of cistanche deserticola and 15 parts of rhizoma polygonati.
Pharmacological analysis of the above Chinese medicinal composition:
monarch drug: cornu Cervi, fructus Leonuri, and flos Caryophylli.
The antler is used for lifting yang qi, the motherwort fruit enters the liver, spleen and lung channels, the smell is all raised, the qi is regulated, the depression is removed, the weight is reduced, and the clove is used for warming yang and lowering qi.
Ministerial drugs: periostracum Cicadae, bombyx Batryticatus, bupleuri radix, curcuma rhizome, herba asari, radix Aconiti lateralis Preparata, herba Lespedezae Cuneatae, semen Sinapis Albae, and fructus Perillae.
The cicada slough and the stiff silkworm jointly dispel wind and relieve spasm, relieve asthma and reduce phlegm, and achieve the anti-allergic and anti-inflammatory effects; bupleuri radix has effects of dispersing stagnated liver qi for relieving qi stagnation, and can promote yang qi, and bupleuri radix, periostracum Cicadae and Bombyx Batryticatus can promote yang.
Turmeric has the effects of promoting qi circulation, dredging channels, reducing turbid yin in yin, reducing inflammatory secretion by using active ingredients of turmeric, and regulating inflammatory cell functions so as to achieve the anti-inflammatory effect.
Asarum herba asari has the actions of warming and dispelling cold, and can lower the adverse flow of qi to relieve cough.
The light accessory tablet warms the distention and fullness, warms the kidney, helps to remove cold phlegm, resists inflammation and improves the immunity of the organism.
The herba inulae enters lung and large intestine meridians, and has the functions of resolving phlegm, relieving cough, resolving fluid retention and relieving asthma.
Semen Sinapis Albae and fructus Perillae have effects of lowering qi, eliminating phlegm, relieving cough and asthma.
The nine ministerial drugs are combined together to be suitable for ascending and descending, and the lung qi is released and lowered, and the whole body qi movement is regulated, so that asthma is self-relieved.
Adjuvant drug: astragalus root, white atractylodes rhizome, ledebouriella root, perilla leaf, dipsacus root and cistanche.
Astragalus and bighead atractylodes rhizome are sweet and warm, and have the effects of replenishing qi, strengthening spleen and consolidating exterior; wind-repellent incense, warm nature, and both internal and external wind can dispel wind and cold, so as to smooth qi movement; the astragalus root is used for achieving the purposes of resisting inflammation and improving the lung function, the bighead atractylodes rhizome is used for treating diseases related to the immune system such as asthma through phagocytosis of cells and regulation of inflammatory reaction, the 20-prevention high-immune-activity function is used for enhancing the body immunity, and the astragalus root, the bighead atractylodes rhizome and the radix sileris are used together, so that the qi-tonifying and exterior-securing capacity can be multiplied.
Perillae She Wenfei can reduce adverse flow of qi, relieve asthma and stop cough.
Radix dipsaci and cistanche salsa are used for tonifying kidney and supporting yang, the concentration of active substances on the alveoli is improved by using the cistanche salsa and the radix dipsaci, and lung tissues are protected from damage, so that airway remodeling is slowed down, and meanwhile, the immunity of an organism is improved.
The preparation method comprises the following steps: rhizoma polygonati.
Rhizoma polygonati has the effects of moistening lung, drying, nourishing yin of lung and kidney, relieving cough, tonifying spleen and tonifying kidney, and utilizing rhizoma polygonati to achieve the effects of resisting inflammation, dilating bronchus and the like.
Compared with the defects and shortcomings of the prior art, the invention has the following beneficial effects:
the traditional Chinese medicine composition takes antler, motherwort fruit and clove as monarch drugs, takes cicada slough, stiff silkworm, radix bupleuri, turmeric, asarum, light aconite, golden-boiling grass, white mustard seed and perilla fruit as ministerial drugs, takes astragalus root, bighead atractylodes rhizome, radix sileris, perilla leaf, teasel root and cistanche as adjuvant drugs, and takes rhizoma polygonati as conductant drugs, the medicines are combined and lifted appropriately, the medicine effects are synergistic, the inside and outside are combined, the lung qi is dispersed and reduced appropriately, and qi and blood of the whole body are smooth, so that the effects of warming lung and reducing phlegm, reducing qi and relieving cough and calming asthma and receiving kidney are achieved. Can be used for treating both principal and secondary symptoms of asthma, and improving symptoms and pulmonary function. Research shows that the medicine has better treatment effect on patients with bronchial asthma in clinical application.
Detailed Description
The present invention will be further described in detail with reference to the following examples, in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
1. The traditional Chinese medicine composition for treating bronchial asthma comprises the following raw materials: cornu Cervi, fructus Leonuri, flos Caryophylli, periostracum Cicadae, bombyx Batryticatus, bupleuri radix, curcuma rhizome, herba asari, radix Aconiti lateralis Preparata, herba Hedyotidis Diffusae, semen Sinapis Albae, fructus Perillae, radix astragali, atractylodis rhizoma, radix Saposhnikoviae, folium Perillae, radix Dipsaci, cistanchis herba, and rhizoma Polygonati.
2. Case analysis
2.1 preparation of watered pills
The weight portions are as follows: 20 parts of antler, 20 parts of motherwort fruit, 9 parts of clove, 10 parts of cicada slough, 20 parts of stiff silkworm, 6 parts of radix bupleuri, 8 parts of turmeric, 9 parts of asarum, 18 parts of thin aconite, 10 parts of golden-point grass, 8 parts of white mustard seed, 12 parts of perilla fruit, 30 parts of astragalus root, 20 parts of bighead atractylodes rhizome, 10 parts of divaricate saposhnikovia root, 10 parts of perilla leaf, 15 parts of teasel root, 15 parts of cistanche deserticola and 15 parts of rhizoma polygonati. The preparation room of Ningxia TCM hospital and TCM research institute uses the technique of watered pill processing and instruments to prepare watered pill. The using method comprises the following steps: 3 times per day, 6g per time, half an hour after meal.
2.2 case cases
400 bronchial asthma patients in four hospitals of the traditional Chinese medicine hospital in Ningxia and traditional Chinese medicine research institute in China, the traditional Chinese medicine hospital in Shizuishan city, the traditional Chinese medicine hospital in salt pond county and the traditional Chinese medicine hospital in Longde county are collected for diagnosis in 10 months in 2018 to 10 months in 2020, 6 follow-up cases are taken off, and 394 cases are observed. Inclusion criteria: meets the diagnosis standard establishment in the bronchial asthma control guidelines issued by the asthma group of the respiratory disease department of China medical society (2020 edition); the medical history is more than or equal to 3 months; the clinical data are complete and reliable, and all the clinical data are used for lung function examination. Exclusion criteria: patients with severe heart, liver and kidney dysfunction or pregnancy, lactation, malignant tumor and asthma persistent state critical symptoms are combined. Of 394 cases, 127 men and 267 women, the minimum age was 14 years, the maximum age was 71 years, and the average age (43.20 ±13.24) was the same. Sex, age, no significant differences (P > 0.05) between each pattern group.
2.3 Lung function examination
By pulmonary function examination, it is determined whether the patient meets asthma diagnosis, and detection is performed by the professional of Ningxia TCM hospital and department of pulmonary diseases of TCM institute, and FEV is recorded 1 ％pred、FEV 1 FVC% change before treatment and after 2 months of treatment.
2.4 criteria for classifying and quantifying symptoms in TCM
Since 394 patients refer to 2002 edition of Chinese medicine New drug clinical study guidelines (trial), grading scores of patients suffering from acute episode asthma of the subject are compared. The scores before and after treatment were recorded in detail, and the primary and secondary symptoms were scored on a scale of 4, with primary symptoms: 0 is normal, 2 is light, 4 is medium, 6 is heavy; secondary symptoms: 0 is normal, 1 is light, 2 is medium, and 3 is heavy.
2.5 statistical methods
After completion of 2 months of clinical observations, all data were collected. Data statistical analysis was performed using SPSS 23.0. With p < 0.05 as the criterion for judging the significance difference, a double-sided test was used. For metering dataDescribing, performing data statistics by using an analysis of variance statistical method.
2.6 results
(1) Chinese medicine main symptom integral comparison for bronchial asthma patientAs shown in table 1:
TABLE 1 integral comparison of the principal symptoms of traditional Chinese medicine in patients with bronchial asthma
(2) Traditional Chinese medicine secondary symptom integral comparison for bronchial asthma patientAs shown in table 2:
table 2 comparison of secondary symptom score in chinese medicine for bronchial asthma patient
(3) Comparison of lung function before and after treatment of patients with bronchial asthmaAs shown in table 1:
TABLE 3 comparison of pulmonary function before and after treatment of patients with bronchial asthma
By observing 394 cases of asthma and cough relieving pills orally taken by patients in Ningxia region, traditional Chinese medicine symptoms, pulmonary function changes and liver and kidney functions of the patients before and after treatment of the asthma are detected by AST (U/L), ALT (U/L), cr (umol/L), blood routine, urine routine and other test indexes, and the like, the patients have no abnormal changes after regular use of treatment medicines. The adverse reaction related to the watered pill does not occur in the treatment process of patients, which indicates that the watered pill has better safety in clinical application. After 2 months of treatment, the main symptoms of asthma patients such as wheeze, cough, expectoration, chest fullness, wheeze and the like are compared before and after treatment, and p is less than 0.05, so that the pill has statistical significance, and the effect of improving the main symptoms of patients by lifting the pill is obvious. The patients have dark complexion, cold limbs, choking cough, flushing, polydipsia, cough, weakness, shortness of breath and other secondary symptoms, and p < 0.05 has statistical significance, thus indicating that the pill for relieving asthma and cough has better treatment effect on the secondary symptoms of patients with bronchial asthma. FEV for lung function of patient before and after treatment 1 ％pred、FEV 1 Comparing with FVC, the two groups have p less than 0.05 and have obvious difference, and the FEV of the lung function is obtained after 2 months of intervention treatment by the water-paste pill 1 ％pred、FEV 1 The FVC is improved before treatment, which shows that the invention can improve the lung function of patients to a certain extent, treat both principal and secondary aspect of the invention, and research shows that the invention has better treatment effect for treating bronchial asthma patients in clinical application.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, and alternatives falling within the spirit and principles of the invention.

Claims (4)

1. The traditional Chinese medicine composition for treating bronchial asthma is characterized by being prepared from the following raw materials in parts by weight: 15-25 parts of antler, 15-25 parts of motherwort fruit, 5-10 parts of clove, 8-15 parts of cicada slough, 15-25 parts of stiff silkworm, 5-10 parts of bupleurum, 5-10 parts of turmeric, 5-10 parts of asarum, 15-20 parts of thin aconite, 8-15 parts of golden-boiling grass, 5-10 parts of white mustard seed, 10-15 parts of perilla seed, 25-35 parts of astragalus root, 15-25 parts of bighead atractylodes rhizome, 15-20 parts of divaricate saposhnikovia root, 8-15 parts of perilla leaf, 12-18 parts of teasel root, 12-18 parts of cistanche deserticola and 12-18 parts of rhizoma polygonati.
2. The traditional Chinese medicine composition for treating bronchial asthma according to claim 1, wherein the traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 20 parts of antler, 20 parts of motherwort fruit, 9 parts of clove, 10 parts of cicada slough, 20 parts of stiff silkworm, 6 parts of radix bupleuri, 8 parts of turmeric, 9 parts of asarum, 18 parts of thin aconite, 10 parts of golden-point grass, 8 parts of white mustard seed, 12 parts of perilla fruit, 30 parts of astragalus root, 20 parts of bighead atractylodes rhizome, 18 parts of divaricate saposhnikovia root, 10 parts of perilla leaf, 15 parts of teasel root, 15 parts of cistanche deserticola and 15 parts of rhizoma polygonati.
3. The traditional Chinese medicine composition for treating bronchial asthma according to claim 1 or 2, wherein the traditional Chinese medicine composition is a watered pill.
4. Use of a Chinese medicinal composition according to claim 1 or 2 for the preparation of a medicament for the treatment of bronchial asthma.
CN202210416245.7A 2022-04-20 2022-04-20 Traditional Chinese medicine composition for treating bronchial asthma Active CN114732887B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210416245.7A CN114732887B (en) 2022-04-20 2022-04-20 Traditional Chinese medicine composition for treating bronchial asthma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210416245.7A CN114732887B (en) 2022-04-20 2022-04-20 Traditional Chinese medicine composition for treating bronchial asthma

Publications (2)

Publication Number Publication Date
CN114732887A CN114732887A (en) 2022-07-12
CN114732887B true CN114732887B (en) 2023-08-22

Family

ID=82282784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210416245.7A Active CN114732887B (en) 2022-04-20 2022-04-20 Traditional Chinese medicine composition for treating bronchial asthma

Country Status (1)

Country Link
CN (1) CN114732887B (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
升降止咳平喘丸治疗轻中度支气管哮喘急性发作期冷哮型临床研究;王成娟等;《广西中医药》;第44卷(第6期);第17-19页，尤其是第17页摘要、右栏倒数第1段，第18页左栏第1段，第19页左栏倒数第1段、右栏第1段 *

Also Published As

Publication number Publication date
CN114732887A (en) 2022-07-12

Similar Documents

Publication Publication Date Title
CN101049415A (en) Preparation of Chinese traditional medicine for treating inflammation of department of gynecology
CN111437355B (en) Traditional Chinese medicine composition and preparation method and application thereof
CN111202802B (en) Traditional Chinese medicine composition for eliminating dampness and ventilating lung and application thereof
CN112353855A (en) Application of traditional Chinese medicine composition in preparation of medicine for adjuvant therapy of novel coronavirus pneumonia
CN105233231A (en) Pharmaceutical composition for treating respiratory diseases
CN104352595A (en) Traditional Chinese medicine for treating allergic rhinitis and preparation method thereof
CN101843840B (en) Chinese medicinal compound granules for treating acute exacerbation of chronic obstructive pulmonary disease
CN103341092B (en) Preparation method of powder for treating atrophic vaginitis
CN102188689B (en) Compound combination medicament for treating COPD, preparation method and application thereof
CN114732887B (en) Traditional Chinese medicine composition for treating bronchial asthma
CN103285284B (en) Medical composition for treating senile vaginitis
CN103301353B (en) Pharmaceutical composition for treating atrophic vaginitis
CN103356932B (en) A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia
CN113648378B (en) Traditional Chinese medicine compound for treating early stage neocoronary pneumonia and application of traditional Chinese medicine compound for treating respiratory tract infection
CN110327437B (en) Traditional Chinese medicine for treating chronic diarrhea and preparation method thereof
CN103301373B (en) Pharmaceutical composition for treating postpartum perineal mucosal lesions
CN108355124B (en) Traditional Chinese medicine composition for treating airway mucus hypersecretion and application thereof
CN103301374B (en) Pharmaceutical composition for treating postpartum non-specificity vaginitis
CN104721388B (en) The Chinese medicine composition and its preparation method and application for treating people at highest risk&#39;s influenza severe
CN108837020A (en) Compound Xinhui tangerine peel lozenge and its preparation method and application
CN103341094B (en) Preparation method of powder for treating vulva squamous epithelial cell hyperplasia
CN101991730A (en) Traditional Chinese medicine compound preparation for treating bronchial asthma and resisting recurrence and preparation method thereof
CN105079225A (en) Application of traditional Chinese medicine combination in preparing drug for treating bronchiectasia
Liu et al. Clinical Application of Asarum in Children with Pulmonary Diseases
Xu TCM and Western Medicine: Diagnosis and Treatment of Novel Coronavirus Pneumonia, A Case Study

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant